The invention relates to novel bone morphogenetic protein 9 (BMP9) variants and to pharmaceutical compositions comprising said variants. The invention also relates to a polypeptide selected from bone morphogenetic protein 10 (BMP10) and a BMP9 variant lacking osteogenic activity, for use in the treatment of a vascular disease or a respiratory disease.
